Literature DB >> 23171918

A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism.

M O Alberti1, J S Deshane, D D Chaplin, L Pereboeva, D T Curiel, J C Roth.   

Abstract

Specific and efficient gene delivery to the lung has been hampered by liver sequestration of adenovirus serotype 5 (Ad5) vectors. The complexity of Ad5 liver tropism has largely been unraveled, permitting improved efficacy of Ad5 gene delivery. However, Kupffer cell (KC) scavenging and elimination of Ad5 still represent major obstacles to lung gene delivery strategies. KC uptake substantially reduces bioavailability of Ad5 for target tissues and compensatory dose escalation leads to acute hepatotoxicity and a potent innate immune response. Here, we report a novel lung-targeting strategy through redirection of Ad5 binding to the concentrated leukocyte pool within the pulmonary microvasculature. We demonstrate that this leukocyte-binding approach retargets Ad5 specifically to lung endothelial cells and prevents KC uptake and hepatocyte transduction, resulting in 165,000-fold enhanced lung targeting, compared with Ad5. In addition, myeloid cell-specific binding is preserved in single-cell lung suspensions and only Ad.MBP-coated myeloid cells achieved efficient endothelial cell transduction ex vivo. These findings demonstrate that KC sequestration of Ad5 can be prevented through more efficient uptake of virions in target tissues and suggest that endothelial transduction is achieved by leukocyte-mediated 'hand-off' of Ad.

Entities:  

Mesh:

Year:  2012        PMID: 23171918      PMCID: PMC3764611          DOI: 10.1038/gt.2012.91

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  48 in total

Review 1.  Genetic targeting of adenoviral vectors.

Authors:  V N Krasnykh; J T Douglas; V W van Beusechem
Journal:  Mol Ther       Date:  2000-05       Impact factor: 11.454

2.  Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo.

Authors:  P N Reynolds; S A Nicklin; L Kaliberova; B G Boatman; W E Grizzle; I V Balyasnikova; A H Baker; S M Danilov; D T Curiel
Journal:  Nat Biotechnol       Date:  2001-09       Impact factor: 54.908

Review 3.  The marginated pool.

Authors:  Wolfgang M Kuebler; Alwin E Goetz
Journal:  Eur Surg Res       Date:  2002 Jan-Apr       Impact factor: 1.745

4.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.

Authors:  R Alemany; D T Curiel
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

5.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.

Authors:  Y Zhang; N Chirmule; G P Gao; R Qian; M Croyle; B Joshi; J Tazelaar; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

6.  A mouse model for adenovirus gene delivery.

Authors:  T Tallone; S Malin; A Samuelsson; J Wilbertz; M Miyahara; K Okamoto; L Poellinger; L Philipson; S Pettersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

7.  Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver.

Authors:  N Tao; G P Gao; M Parr; J Johnston; T Baradet; J M Wilson; J Barsoum; S E Fawell
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

8.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12.

Authors:  J V Maizel; D O White; M D Scharff
Journal:  Virology       Date:  1968-09       Impact factor: 3.616

9.  Coagulation factor X activates innate immunity to human species C adenovirus.

Authors:  Konstantin Doronin; Justin W Flatt; Nelson C Di Paolo; Reeti Khare; Oleksandr Kalyuzhniy; Mauro Acchione; John P Sumida; Umeharu Ohto; Toshiyuki Shimizu; Sachiko Akashi-Takamura; Kensuke Miyake; James W MacDonald; Theo K Bammler; Richard P Beyer; Frederico M Farin; Phoebe L Stewart; Dmitry M Shayakhmetov
Journal:  Science       Date:  2012-09-27       Impact factor: 47.728

10.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

Authors:  Steven E Raper; Narendra Chirmule; Frank S Lee; Nelson A Wivel; Adam Bagg; Guang-ping Gao; James M Wilson; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

View more
  7 in total

1.  A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.

Authors:  Mahtab Moayeri; Clinton E Leysath; Jacqueline M Tremblay; Catherine Vrentas; Devorah Crown; Stephen H Leppla; Charles B Shoemaker
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

Review 2.  Advances in Alpha-1 Antitrypsin Gene Therapy.

Authors:  Reka Lorincz; David T Curiel
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

3.  COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.

Authors:  Victor Prima; Lyudmila N Kaliberova; Sergey Kaliberov; David T Curiel; Sergei Kusmartsev
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

4.  Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice.

Authors:  Mahtab Moayeri; Jacqueline M Tremblay; Michelle Debatis; Igor P Dmitriev; Elena A Kashentseva; Anthony J Yeh; Gordon Y C Cheung; David T Curiel; Stephen Leppla; Charles B Shoemaker
Journal:  Clin Vaccine Immunol       Date:  2016-01-06

5.  The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.

Authors:  Zhi Hong Lu; Sergey Kaliberov; Jingzhu Zhang; Barbara Muz; Abdel K Azab; Rebecca E Sohn; Lyudmila Kaliberova; Yingqiu Du; David T Curiel; Jeffrey M Arbeit
Journal:  Lab Invest       Date:  2014-06-23       Impact factor: 5.662

6.  A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting.

Authors:  Zhi Hong Lu; Igor P Dmitriev; Douglas E Brough; Elena A Kashentseva; Jie Li; David T Curiel
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

Review 7.  Nucleic Acid-Based Therapeutics for Pulmonary Diseases.

Authors:  Jing Chen; Yue Tang; Yun Liu; Yushun Dou
Journal:  AAPS PharmSciTech       Date:  2018-10-18       Impact factor: 3.246

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.